Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmana, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert, Ora Rosengarten, Niklas Loman, Jane D Robertson, Helen Mann, Bella Kaufman
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2016
Awarded by AstraZeneca
This study was sponsored by AstraZeneca (as part of NCT01078662). We thank Martin Goulding from Mudskipper Business Ltd., who provided medical writing assistance, which was funded by AstraZeneca.